" Neutrocheck® would have made a huge difference to me during
my cancer treatment and recovery. Catching an infection
was a constant worry as this could be life-threatening if I was
neutropenic; any sign of a fever would mean a trip to A&E.
"
Jenni, Macmillan Innovation Community member, diagnosed
with Acute Myeloid Leukaemia
" Having Neutrocheck® receive further validation through
investment from Macmillan Cancer Support is incredibly valuable,
both in terms of raising the profile of the innovation but also
in terms of ongoing support. This investment allows us to work
closely with Macmillan to drive the future of better cancer care.
"
Umaima Ahmad, CEO of 52 North Health
We engineered more innovative fundraising activity.
In 2023 we identified new ways for Macmillan to generate its income in the
future. We began to test and build our new funding approach developing five
new pilot innovations, including an exploration of the pre-loved retail market.
By developing new routes to fund our vital support services we will increase
Macmillan's financial resilience.
We worked with new healthcare innovation partners.
Macmillan started working with new innovation partners in the health and
social care sectors to develop alternative ways to help people with cancer
in an everchanging health landscape. We launched the Macmillan Innovation
Impact Investment Portfolio. Our aim is to invest £3.5 million in dynamic startup
businesses that are developing ground-breaking cancer care innovations
between now and 2025. £100,000 of this was invested in 2023.
Innovation investment - Neutrocheck®.
As part of The Macmillan Innovation Impact Investment Portfolio, we made
our first investment of £100,000 in 52 North Health, the developers of
Neutrocheck®. This portable medical device is an at-home blood finger prick
test that assesses the risk level of neutropenic sepsis in patients.
The condition is a life-threatening, whole-body reaction to infection, which
can be particularly dangerous to people with cancer. Chemotherapy patients
can get neutropenic sepsis due to a suppressed immune system, and it can be
fatal. Neutrocheck® aims to help people undergoing chemotherapy to act early,
avoiding unnecessary trips to hospital.
Neutrocheck®, an at-home test
for neutropenic sepsis
41
Environmental, social
and governance review
Financial review
Strategic report
Overview Financial statements Thank you
4